Biomerieux Alliance, the holding group that includes the diagnostics company BioMerieux and the French biotechnology group Transgene, is to be prepared for a stock exchange listing in three to five years time, according to Alain Merieux, who has a controlling 67% interest in the group.
Mr Merieux and the other shareholder, the CGIP group, plan to inject some 300 million French francs ($60.2 million) of new capital into Biomerieux Alliance. The core of the ensemble is BioMerieux, which has reported sustained growth in recent years.
In 1994, despite the 5% downturn in the European diagnostics market, BioMerieux increased its sales by 10% to 2.4 billion francs, with diagnostic tests for the detection of infectious diseases making up 80% of total turnover. Mr Merieux says the growth can be accelerated by alliances and acquisitions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze